Technology

Endevica's drug discovery team works with cyclized, synthetic peptidomimetics to target G-Protein Coupled Receptors (GPCRs).

Endevica's first drug target was melanocortin-4, a GPCR that's expressed in the hypothalamus. Our experiments eventually resulted in molecules that showed in vitro activation of melanocortin receptors on HEK cells. Further selection and refinement led to molecules that were also effective in activating receptors in vivo - meaning that Endevica's platform technology is able to drive peripherally-administered molecules across the BBB to reach GPCRs in the central nervous system. This is a remarkable therapeutic advance.

Larger peptidomimetics have many advantages over traditional small molecules for many therapeutic areas. Larger, hydrophilic molecules tend to have far fewer off-target effects than small molecules. They are also amenable to faster development cycles and simpler formulations.

Today, Endevica Bio is leveraging this platform on new GPCR targets into a proprietary drug development pipeline.

Scroll to Top